Hepatotoxicity and hepatic metabolism of available drugs: current problems and possible solutions in preclinical stages

Bibliography

• Scott EF, James HG, Kenneth RM. Current diagnosis & treatment in gastroenterology. Lang Medical Books/McGraw-Hill: New York; 2003
   Google Scholar
• Temple R. Policy development in regulatory approval. Stat Med 2002;21:2939-48
   PubMed Web of Science ®Google Scholar
• Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;31:474-85
   Google Scholar
• Temple R. Hepatotoxicity through the years: impact on the FDA. February 2001. Available from: www.fda.gov/cder/livertox/meeting2001
   Google Scholar
• Abboud G, Kaplowitz N. Drug-induced liver injury. Drug Saf 2007;30:277-94
   PubMed Web of Science ®Google Scholar
• Xu JJ, Henstock PV, Dunn MC, Cellular imagaing predictions of clinical drug-indued liver injury. Tox Sci 2008;105:97-105
   PubMed Web of Science ®Google Scholar
• Temple RJ. Hepatotoxicity through the years: impact on the FDA. Available from: http://www.fda.gov/cder/livertox/Presentations/im1389/sld001.htm. [Accessed 20 January 2006]
   Google Scholar
• Holden A. Detecting and investigating drug-induced adverse events: the international Serious Adverse Event Consortium's experience. 2008. Available from: www.fda.gov/cder/livertox
   Google Scholar
• Russo MW, Galanko JA, Shrestha R, Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004;10:1018-23
   PubMed Web of Science ®Google Scholar
• Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008;9:310-22
   PubMed Web of Science ®Google Scholar
• Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002;22:145-55
   PubMed Web of Science ®Google Scholar
• Ostapowicz G, Fontana RJ, Schiødt FV, Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947-54
   PubMed Web of Science ®Google Scholar
• Kramer JA, Sagartz JE, Morris DL. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat Rev Drug Discov 2007;6:636-49
   PubMed Web of Science ®Google Scholar
• Fura A. Role of pharmacologically active metabolites in drug discovery and development. Drug Discov Today 2006;11:133-42
   PubMed Web of Science ®Google Scholar
• Mertes G. Safety and efficacy of acarbose in the treatment of type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract 2001;52:193-04
   PubMed Web of Science ®Google Scholar
• Carrascosa M, Pascual F, Aresti S. Acarbose-induced acute severe hepatotoxicity. Lancet 1997;349:698-9
   PubMed Web of Science ®Google Scholar
• Fujimoto Y, Ohhira M, Miyokawa N, Acarbose-induced hepatic injury. Lancet 1998;351:340
   PubMed Web of Science ®Google Scholar
• Hsiao SH, Liao LH, Cheng PN, Wu TJ. Hepatotoxicity associated with acarbose therapy. Ann Pharmacother 2006;40:151-4
   PubMed Web of Science ®Google Scholar
• Lee WM. Drug-induced hepatotoxicity. N Engl J Med 1995;26:1118-27
   Google Scholar
• Biagi RW, Bapat BN. Intrahepatic obstructive jaundice from amitriptyline. Br J Psychiatry 1967;113:1113-14
   PubMed Web of Science ®Google Scholar
• Morgan DH. Jaundice associated with amitriptyline. Br J Psychiatry 1969;115:105-6
   PubMed Web of Science ®Google Scholar
• Yon J, Anuras S. Hepatitis caused by amitriptyline therapy. JAMA 1975;232:833-4
   PubMed Web of Science ®Google Scholar
• Anderson BN, Henrikson IR. Jaundice and eosinophilia associated with amitriptyline. J Clin Psychiatry 1978;39:730-1
   PubMed Web of Science ®Google Scholar
• Cunningham ML. Acute hepatic necrosis following treatment with amitriptyline and diazepam. Br J Psychiatry 1965;111:1107-09
   PubMedGoogle Scholar
• Danan G, Bernuau J, Moullot X, Amitriptyline-induced fulminant hepatitis. Digestion 1984;30:179-84
   PubMed Web of Science ®Google Scholar
• Berkelhammer C, Kher N, Berry C, Largosa A. Nortriptylineinduced fulminant hepatic failure. J Clin Gastroenterol 1995;20:54-6
   PubMed Web of Science ®Google Scholar
• Pedersen AM, Enevoldsen HK. Nortriptyline-induced hepatic failure. Ther Drug Monit 1996;18:100-2
   PubMed Web of Science ®Google Scholar
• Martinez-Mir JM, Ferrer V, Palop L, Are the adverse drug reactions of amoxicillin and amoxicillin–clavulanic acid similar? Pharmacoepidemiol Drug Saf 1996;5:247-54
   PubMedGoogle Scholar
• Caron F, Ducrotte P, Lerebours E, Effects of amoxicillin–clavulanate combination on the motility of the small intestine in human beings. Antimicrob Agents Chemother 1991;35:1085-8
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 1997;156:1327-32
   Web of Science ®Google Scholar
• Berg P, Hahn EG. Hepatotoxic reactions induced by b-lactamase inhibitors. Eur J Med Res 2001;6:535-42
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Obaid Shakil A, Greenson JK, Acute liver failure due to amoxicillin and amoxicillin/clavulanate. Dig Dis Sci 2005;50:1785-90
   PubMed Web of Science ®Google Scholar
• Brown SJ, Desmond PV. Hepatotoxicity of antimicrobial agents. Semin Liver Dis 2002;22:157-67
   PubMed Web of Science ®Google Scholar
• Salvo F, Giovanni P, Ugo M, Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy. J Antimicrob Chemother 2007;60:121-26
   PubMed Web of Science ®Google Scholar
• Bolzan H, Spatola J, Castelletto R, Curciarello J. Intrahepatic cholestasis induced by amoxicillin alone. Gastroenterol Hepatol 2000;23:237-39
   PubMedGoogle Scholar
• Cundiff J, Joe S. Amoxicillin-clavulanic acid-induced hepatitis. Am J Otolaryngol 2007;28:28-30
   PubMed Web of Science ®Google Scholar
• Larrey D, Vial T, Micaleff A, Hepatitis associated with amoxicillinclavulanic acid combination report of 15 cases. Gut 1992;33:368-71
   PubMed Web of Science ®Google Scholar
• Hautekeete ML, Brenard R, Horsmans Y, Liver injury related to amoxicillinclavulanic acid: interlobular bileductlesion and extrahepatic manifestations. J Hepatol 1995;22:71-7
   PubMed Web of Science ®Google Scholar
• Tortajada GM, Ferrer FA, Gracia AM, Hypersensitivity to clavulanic acid in children. Allergol Immunopathol (Madr) 2008;36:308-10
   PubMed Web of Science ®Google Scholar
• Ryan J, Dudley F. Cholestatic hepatitis associated with clavulanic acid. Gut 1992;33:1583
   PubMed Web of Science ®Google Scholar
• Yoon JY, Min SY, Park JY, A case of allopurinol-induced granulomatous hepatitis with ductopenia and cholestasis. Korean J Hepatol 2008;14:97-101
   PubMedGoogle Scholar
• Raper R, Ibels L, Lauer C, Fulminant hepatic failure due to allopurinol. Aust N Z J Med 1984;14:63-5
   PubMedGoogle Scholar
• Morse RM, Valenzuela GA, Greenwald TP, Amiodarone-induced liver toxicity. Ann Intern Med 1988;109:838-40
   PubMed Web of Science ®Google Scholar
• Lewis JH, Ranard RC, Caruso A, Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology 1989;9:679-85
   PubMed Web of Science ®Google Scholar
• Fromenty B, Fisch C, Berson A, Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II. J Pharmacol Exp Ther 1990;255:1377-84
   PubMed Web of Science ®Google Scholar
• Fromenty B, Fisch C, Labbe G, Amiodarone inhibits the mitochondrial betaoxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J Pharmacol Exp Ther 1990;255:1371-76
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Torok M, Hanni A, Mechanisms of benzarone and benzbromaroneinduced hepatic toxicity. Hepatology 2005;41:925-35
   PubMed Web of Science ®Google Scholar
• Spaniol M, Brooks H, Auer L, Development and characterization of an animal model of carnitine deficiency. Eur J Biochem 2001;268:1876-87
   PubMedGoogle Scholar
• Flaharty KK, Chase SL, Yaghsezian HM, Rubin R. Hepatotoxicity associated with amiodarone therapy. Pharmacotherapy 1989;9:39-44
   PubMed Web of Science ®Google Scholar
• Singhal A, Ghosh P, Khan SA. Low dose amiodarone causing pseudo-alcoholic cirrhosis. Age Ageing 2003;32:224-25
   PubMed Web of Science ®Google Scholar
• Puli SR, Fraley MA, Puli V, Hepatic cirrhosis caused by low-dose oral amiodarone therapy. Am J Med Sci 2005;330:257-61
   PubMed Web of Science ®Google Scholar
• Sastri SV, Diaz-Arias AA, Marshall J. Can Pancreatitis be Associated with Amiodarone Hepatotoxicity? J Clin Gastroen 1990;12:70-73
   PubMed Web of Science ®Google Scholar
• Casavant MJ, Blake K, Griffith J, Consequences of use of anabolic androgenic steroids. Pediatr Clin North Am 2007;54:677-90
   PubMed Web of Science ®Google Scholar
• Kafrouni MI, Anders RA, Verma S. Hepatotoxicity associated with dietary supplements containing anabolic steroids. Clin Gastroenterol Hepatol 2007;5:809-12
   PubMed Web of Science ®Google Scholar
• Socas L, Zumbado M, Perez-Luzardo O, Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br J Sports Med 2005;39:e27
   PubMed Web of Science ®Google Scholar
• Gorayski P, Thompson CH, Subhash HS, Thomas AC. Hepatocellular carcinoma associated with recreational anabolic steroid use. Br J Sports Med 2008;42:74-5
   PubMed Web of Science ®Google Scholar
• Soe KL, Soe M, Gluud C. Liver pathology associated with the use of anabolicandrogenic steroids. Liver 1992;12:73-9
   PubMedGoogle Scholar
• Nadell J, Kosek J. Peliosis hepatis. Twelve cases associated with oral androgen therapy. Arch Pathol Lab Med 1977;101:405-10
   PubMed Web of Science ®Google Scholar
• Dickerman RD, Pertusi RM, Zachariah NY, Anabolic steroid-induced hepatotoxicity: is it overstated? Clin J Sport Med 1999;9:34-9
   PubMed Web of Science ®Google Scholar
• de Boer NK, Mulder CJ, van Bodegraven AA. Myelotoxicity and hepatotoxicity during azathioprine therapy. Neth J Med 2005;63:444-6
   PubMed Web of Science ®Google Scholar
• Gardiner SJ, Gearry RB, Burt MJ, Severe hepatotoxicity with high 6-methylmercaptopurine nucleotide concentrations after thiopurine dose escalation due to low 6-thioguanine nucleotides. Eur J Gastroenterol Hepatol 2008;20:1238-42
   PubMed Web of Science ®Google Scholar
• Shaye OA, Yadegari M, Abreu MT, Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients. Am J Gastroenterol 2007;102:2488-94
   PubMed Web of Science ®Google Scholar
• Majed O, Arie O. Hepatotoxicity due to azathioprine in a patient with nephritic syndrome. Hepatol Res 2000;16:139-44
   Web of Science ®Google Scholar
• De Pinho RA, Goldberg CS, Lefkowitch JH. Azathioprine and the liver. Evidence favoring idiosyncratic, mixed cholestatichepatocellular injury in humans. Gastroenterology 1984;86:162-5
   PubMed Web of Science ®Google Scholar
• Sparberg M, Simon N, Del Greco F. Intrahepatic cholestasis due to azathioprine. Gastroenterology 1969;57:439-41
   PubMed Web of Science ®Google Scholar
• Degott C, Rueff B, Kreis H, Peliosis hepatis in recipients of renal transplants. Gut 1978;19:748-53
   PubMed Web of Science ®Google Scholar
• Gerlag PGG, van Hooff JP. Hepatic sinusoidal dilatation with portal hypertension during azathioprine treatment: a cause of chronic liver disease after kidney transplantation. Transplant Proc 1987;29:3699-03
   Google Scholar
• Weitz H, Gokel JM, Loesche K, Venoocclusive disease of the liver in patients receiving immunosuppressive therapy. Virchows Arch 1982;395:245-56
   Web of Science ®Google Scholar
• Katzka DA, Saul SH, Jorkasky D, Azathioprine and hepatic veno-occlusive disease in renal transplanted patients. Gastroenterology 1986;90:446-54
   PubMed Web of Science ®Google Scholar
• Nataf C, Feldmann G, Lebrec D, Idiopathic portal hypertension (perisinusoidal fibrosis) after renal transplantation. Gut 1979;20:531-7
   PubMed Web of Science ®Google Scholar
• Haboubi NY, Ali HH, Whitwell HL, Ackrill P. Role of endothelial cell injury in the spectrum of azathioprineinduced liver disease after renal transplant: light microscopy and ultrastructural observations. Am J Gastroenterol 1988;83:256-61
   PubMed Web of Science ®Google Scholar
• Alvaro D, Onetti-Muda A, Moscatelli R, Attili AF. Acute cholestatic hepatitis induced by bupropion prescribed as pharmacological support to stop smoking. A case report. Dig Liver Dis 2001;33:703-6
   PubMedGoogle Scholar
• Humayun F, Shehab TM, Tworek JA, Fontana RJ. A fatal case of bupropion (Zyban) hepatotoxicity with autoimmune features: Case report. J Med Case Reports 2007;1:88
   PubMedGoogle Scholar
• Oslin DW, Duffy K. The rise of serum aminotransferases in a patient treated with bupropion. J Clin Psychopharmacol 1993;13:364-5
   PubMed Web of Science ®Google Scholar
• Grander W, Eller P, Fuschelberger R, Tilg H. Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C. Eu J Clin Investig 2006;36:67-70
   PubMed Web of Science ®Google Scholar
• Fattinger K, Funk C, Pantze M, The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 2001;69:223-31
   PubMed Web of Science ®Google Scholar
• Nagai Y, Okada E, Mihara S, Severe liver dysfunction due to bosentan in a patient with mixed connective tissue disease. Eur J Dermatol 2008;18:190-1
   PubMed Web of Science ®Google Scholar
• Hunter EB, Johnston PE, Tanner G, Bromfenac(Duract)-associated hepatic failure requiring liver transplantation. Am J Gastroenterol 1999;94:2299-301
   PubMed Web of Science ®Google Scholar
• Moses PL, Schroeder B, Alkhatib O, Severe hepatotoxicity associated with bromfenac sodium. Am J Gastroenterol 1999;94:1393-96
   PubMed Web of Science ®Google Scholar
• Trey C, Davidson CS. The management of fulminant hepatic failure. In: Popper H, Schaffner F, editors. Progress in liver diseases. Grune & Stratton: New York; 1970. p. 282-92
   Google Scholar
• Rabkin JM, Smith MJ, Sl Orloff, Fatal fulminant hepatitis associated with bromfenac use. Ann Pharmacother 1999;33:945-47
   PubMed Web of Science ®Google Scholar
• Crantock L, Prentice R, Powell L. Cholestatic jaundice associated with captopril therapy. J Gastroenterol Hepatol 1991;6:528-30
   PubMed Web of Science ®Google Scholar
• Putterman C, Livshitz T. Captopril-induced liver dysfunction. Harefuah 1991;121:92-3
   PubMedGoogle Scholar
• Nissan A, Spira RM, Seror D, Ackerman Z. Captopril-associated ‘pseudocholangitis’. A case report and review of the literatureArch Surg 1996;131:670-1
   Google Scholar
• Schattner A, Kozak N, Friedman J. Captopril-induced jaundice: report of 2 cases and a review of 13 additional reports in the literature. Am J Med Sci 2001;322:236-40
   PubMed Web of Science ®Google Scholar
• Larrey D, Geneve J, Pessayre D, Prolonged Cholestasis After Cyproheptadine- Induced Acute Hepatitis. J Clin Gastroenterol 1987;9: 102.04
   PubMed Web of Science ®Google Scholar
• Freneaux E, Larrey D, Berson A, Hepatitis caused by cyproheptadine (Periactine). A case and review of the literature. Gastroenterol Clin Biol 1988;12:573-5
   PubMed Web of Science ®Google Scholar
• Henry DA, Lowe JM, Donnelly T. Jaundice during cyproheptadine treatment. Br Med J 1978;25:753
   Google Scholar
• Aygün C, Kocaman O, Gurbuz Y, Clindamycin-induced acute cholestatic hepatitis. World J Gastroenterol 2007;13:5408-10
   PubMed Web of Science ®Google Scholar
• Elmore M, Rissing JP, Rink L, Brooks GF. Clindamycin-associated hepatotoxicity. Am J Med 1974;57:627-30
   PubMed Web of Science ®Google Scholar
• Fass RJ, Saslaw S. Clindamycin: clinical and laboratory evaluation of parenteral therapy. Am J Med Sci 1972;263:369-82
   Web of Science ®Google Scholar
• Fass RJ, Scholand JR, Hodges GR, Saslaw S. Clindamycin in the treatment of serious anaerobic infections. Ann Intern Med 1973;78:853-59
   PubMed Web of Science ®Google Scholar
• Williams H. Clindamycin and benzoyl peroxide combined was more effective than either agent alone or placebo for acne vulgaris. Evid Based Med 2009;14:85
   PubMedGoogle Scholar
• Levander HG. Granulomatous hepatitis in a patient receiving carbamazepine. Acta Med Scand 1980;208:333-35
   PubMed Web of Science ®Google Scholar
• Levy M, Goodman MW, Van Dyne BJ, Sumner HW. Granulomatous hepatitis secondary to carbamazepine. Ann Intern Med 1981;95:64-5
   PubMed Web of Science ®Google Scholar
• Mitchell MC, Boitnott JK, Arregui A, Maddrey WC. Granulomatous hepatitis associated with carbamazepine therapy. Am J Med 1981;71:733-35
   PubMed Web of Science ®Google Scholar
• Hopen G, Nesthus I, Laerum OD. Fatal carbamazepineassociated hepatitis. Report of two cases. Acta Med Scand 1981;210:333-35
   PubMed Web of Science ®Google Scholar
• Rigau-Canardo J, Bruguera M, Sese J, Morlans G. Acute cholestatic hepatitis due to carbamazepine. Gastroenterol Clin Biol 1984;8:769-70
   PubMed Web of Science ®Google Scholar
• Larrey D, Antoine H, Dominiqe P, Carbamazepine-induced acute cholangitis. Dig Dis Sci 1987;32:554-57
   PubMed Web of Science ®Google Scholar
• Morales-Diaz M, Pinilla-Roa E, Ruiz I. Suspected carbamazepine-induced hepatotoxicity. Pharmacotherapy 1999;9:252-5
   Google Scholar
• Wadhawan M, Tyagi P, Malhotra V, Reversible cholestatic hepatitis due to carbamazepine in an adolescent. Indian J Gastroenterol 2005;24:172-73
   PubMedGoogle Scholar
• Hadzic N, Portmann B, Davies ET, Acute liver failure induced by carbamazepine. Arch Dis Child 1990;65:315-7
   PubMed Web of Science ®Google Scholar
• Forbes GM, Jeffrey GP, Shilkin KB, Reed WD. Carbamazepine hepatotoxicity: another cause of the vanishing bile duct syndrome. Gastroenterology 1992;102:1385-88
   PubMed Web of Science ®Google Scholar
• Farrell GC. Drug-induced liver disease. Churchill Livingstone: Edinburgh; 1994
   Google Scholar
• Friis H, Andreasen PB. Drug-induced hepatic injury. An analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med 1992;232:133-8
   PubMed Web of Science ®Google Scholar
• Stricker BHCh, Biour M, Wilson JHP. Individual agents: drugs. In: Stricker B, editor, Druginduced hepatic injury. Drug-induced disorders, Vol. 5. Elsevier: Amsterdam; 1995. p. 71-524
   Google Scholar
• Saeian K, Rajender-Reddy K. Hepatotoxicity of psychotropic drugs and drugs of abuse. In: Kaplowitz N, DeLeve LD, editors, Drug-induced liver disease. Marcel Dekker: New York; 2003. p. 447-69
   Google Scholar
• Derby LE, Perez Gutthann S, Jick H, Dean AD. Liver disorders in patients receiving chlorpromazine or isoniazid. Pharmacotherapy 1993;13:353-8
   PubMed Web of Science ®Google Scholar
• Cook GC, Sherlock S. Jaundice and its relation to therapeutic agents. Lancet 1965;175-9
   PubMed Web of Science ®Google Scholar
• Dickes R, Schenker V, Deutsch L. Serial liver function and blood studies in patients receiving chlorpromazine. New Eng J Med 1957;256
   Google Scholar
• Edmondson HA, B Henderson, B Benton. Liver-cell adenomas associated with use of oral contraceptives. New Eng J Med 1976;294:470-72
   PubMed Web of Science ®Google Scholar
• O'Connor J. Hepatotoxicity and the oral contraceptives. Ann Intern Med 1977;86:118-9
   PubMed Web of Science ®Google Scholar
• Bartók I, Garas S, Szabó L. Letter: oral contraceptives and benign liver tumour. Lancet 1976;28:479-10
   Google Scholar
• Mant JW, Vessey MP. Trends in mortality from primary liver cancer in England and Wales 1975-92: influence of oral contraceptives. Br J Cancer 1995;72:800-3
   PubMed Web of Science ®Google Scholar
• Lindberg MC. Hepatobiliary complications of oral contraceptives. J Gen Intern Med 1992;7:199-209
   PubMed Web of Science ®Google Scholar
• Ferrara BE, Rutland ED. Liver tumor in long-term user of oral contraceptives. Postgrad Med 1988;84:107-9
   PubMed Web of Science ®Google Scholar
• Kapp N, Tilley IB, Curtis KM. The effects of hormonal contraceptive use among women with viral hepatitis or cirrhosis of the liver: a systematic review. Contraception 2009;80:381-6
   PubMed Web of Science ®Google Scholar
• Goyal RK, Srivastav D, Lessnau KD. Clopidogrel-induced hepatocellular injury and cholestatic jaundice in an elderly patient: case report and review of the literature. Pharmacotherpay 2009;29:608-12
   PubMed Web of Science ®Google Scholar
• Ng JA, Goldberg N, Tafreshi MJ. Clopidogrel-induced hepatotoxicity and fever. Pharmacotherapy 2006;26:1023-6
   PubMed Web of Science ®Google Scholar
• Beltran-Robles ME, Saavedra M, Sanchez-Muñoz D, Romero-Gomez M. Hepatotoxicity induced by clopidogrel. J Hepatol 2004;40:560-2
   PubMed Web of Science ®Google Scholar
• Chau TN, Yim KF, Mok NS, Clopidogrel-induced hepatotoxicity after percutaneous coronary stenting. Hong Kong Med J 2005;11:414-6
   PubMedGoogle Scholar
• Banks AT, Zimmerman HJ, Ishak KG, Harter JG. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the FDA as adverse reactionns. Hepatology 1995;22:820-7
   PubMed Web of Science ®Google Scholar
• Boelsterli UA. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 2003;192:307-22
   PubMed Web of Science ®Google Scholar
• Purcell P, Henry D, Melville G, Diclofenac hepatitis. Gut 1991;32:1381-85
   PubMed Web of Science ®Google Scholar
• Walker AM. Walker, Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs. Arthritis Rheum 1997;40:201-08
   PubMed Web of Science ®Google Scholar
• Lewis JH. Nonsteroidal anti-inflammatory drugs: pathology and clinical presentation of hepatotoxicity. In: Kaplowitz N, DeLeve LD, editors, Drug-induced liver disease. Marcel Dekker: New York; 2003. p. 377-404
   Google Scholar
• Sgro F, Clinard K, Ouazir H, Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002;36:451-55
   PubMed Web of Science ®Google Scholar
• Utili R, Boitnott JK, Zimmerman HJ. Dantrolene-associated hepatic injury. Incidence and character. Gastroenterology 1977;72:610-16
   PubMed Web of Science ®Google Scholar
• Wilkinson SP, Portmann B, Williams R. Hepatitis from dantrolene sodium. Gut 1979;20:33-36
   PubMed Web of Science ®Google Scholar
• Chan CH. Dantrolene sodium and hepatic injury. Neurology 1990;40:1427-32
   PubMed Web of Science ®Google Scholar
• Rabkin JM, Corless CL, Orloff SL, Liver transplantation for disulfiram induced hepatic failure. Am J Gastroenterol 1998;93:830-31
   PubMed Web of Science ®Google Scholar
• Mendenhall M. Disulfiram-induced fulminant hepatic failure in an active duty soldier. Mil Med 2004;169:671-72
   PubMed Web of Science ®Google Scholar
• Björnsson E, Nordlinder H, Olsson R. Clinical characteristics and prognostic markers in disulfiram-induced liver injury. J Hepatol 2006;44:791-97
   PubMed Web of Science ®Google Scholar
• Keeffe EB, Smith FW. Disulfiram hypersensitivity hepatitis. J Am Med Assoc 1974;230:435-36
   Web of Science ®Google Scholar
• Ranek L, Buch Andreasen P. Disulfiram hepatotoxicity. Br Med J 1977;2:94-6
   PubMed Web of Science ®Google Scholar
• Morris SJ, Kanner R, Chiprut RO, Schiff ER. Disulfiram hepatitis. Gastroenterology 1978;75:100-2
   PubMed Web of Science ®Google Scholar
• Kristensen ME. Toxic hepatitis induced by disulfiram in a non-alcoholic. Acta Med Scand 1981;209:335-36
   PubMed Web of Science ®Google Scholar
• Bartle WR, Fisher MM, Kerenyi N. Disulfiram-induced hepatitis. Report of two cases and review of the literature. Dig Dis Sci 1985;30:834-7
   PubMed Web of Science ®Google Scholar
• Schade RR, Gray JA, Dekker RR, Fulminant hepatitis associated with disulfiram. Report of a case. Arch Intern Med 1983;143:1271-3
   PubMed Web of Science ®Google Scholar
• Mason NA. Disulfiram-induced hepatitis: case report and review of the literature. DICP 1989;23:872-5
   PubMedGoogle Scholar
• Forns J, Caballeria M, Bruguera JM, Disulfiram-induced hepatitis. Report of four cases and review of the literature. J Hepatol 1994;21:853-7
   PubMed Web of Science ®Google Scholar
• Pariente EA, Pessayre D, Bernuau J, Dihydralazine hepatitis: report of a case and review of the literature. Digestion 1983;27:47-52
   PubMed Web of Science ®Google Scholar
• Nataf J, Bernuau J, Larrey D, A new anti-liver microsome antibody: a specific marker of dihydralazine-induced hepatitis. Gastroenterology 1986;90:1751
   Web of Science ®Google Scholar
• Reinhardt M, Machnik G, Krombholz B, Jahn G. The so-called dihydralazine hepatitis. A contribution to the pathogenesis. Dtsch Z Verdau Stoffwechselkr 1985;45:283-94
   PubMedGoogle Scholar
• Roschlau G. Dihydralazine-induced hepatitis with bridging necrosis. A clinical pathologic survey of 20 cases. Zentralbl Allg Pathol 1983;127:385-93
   PubMedGoogle Scholar
• Bas V, Erkan T, Caliskan S, Toxic hepatitis due to enalapril in childhood. Pediatr Int 2003;45:755-7
   PubMed Web of Science ®Google Scholar
• Jeserich M, Ihling C, Allgaier HP, Acute liver failure due to enalapril. Herz 2000;25:689-93
   PubMed Web of Science ®Google Scholar
• González de la Puente MA, Calderón E, Espinosa R, Fatal hepatotoxicity associated with enalapril. Ann of Pharmacother 2001;35:1492
   PubMed Web of Science ®Google Scholar
• Valle R, Carrascosa M, Cillero L, Perez-Castrillon JL. Enalapril-induced hepatotoxicity. Ann of Pharmacother 1993;27:1405
   PubMed Web of Science ®Google Scholar
• Macías FM, Campos FR, Salguero TP, Ductopenic hepatitis related to Enalapril. J Hepatol 2003;39:1091-92
   PubMed Web of Science ®Google Scholar
• Gholson CF, Warren GH. Fulminant hepatic failure associated with intravenous erythromycin lactobionate. Arch Intern Med 1990;150:215-6
   PubMed Web of Science ®Google Scholar
• Zafrani ES, Ishak KG, Rudzki C. Cholestatic and hepatocellular injury associated with erythromycin esters: report of nine cases. Dig Dis Sci 1979;24:385-96
   PubMed Web of Science ®Google Scholar
• Derby LE, Jick H, Henry DA, Dean AD. Erythromycin-associated cholestatic hepatitis. Med J Aust 1993;158:600-2
   PubMed Web of Science ®Google Scholar
• Wysowsk DK, Fourcroy JL. Flutamide hepatotoxicity. J Urol 1996;155:209-12
   PubMed Web of Science ®Google Scholar
• Gomez JL, Dupont A, Cusan L, Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am J Med 1992;92:465-70
   PubMed Web of Science ®Google Scholar
• Dourakis SP, Alexopolou AA, Hadziyannis SJ. Fulminant hepatitis after flutamide treatment. J Hepatol 1994;20:350-53
   PubMed Web of Science ®Google Scholar
• Corkery JC, Bihrle W, McCaffrey JA, Flutamide-related fulminant hepatic failure. J Clin Gastroenterol 1991;13:364-65
   PubMed Web of Science ®Google Scholar
• Muller S, Iversen P, Franzmann MB. Flutamide-induced liver failure. J Hepatol 1990;10:346-49
   PubMed Web of Science ®Google Scholar
• Pellock JM, Brodie MJ. Felbamate: 1997 Update. Epilepsia 1997;38:261-4
   Google Scholar
• Felbatol. Felbatol [product monograph], 2004. Somerset, MedPointe Pharmaceuticals, NJ
   Google Scholar
• Pellock JM. Felbamate. Epilepsia 1999;40(Suppl 5):S57-62
   PubMedGoogle Scholar
• Bica I, McGovern B, Dhar R, Increasing mortality due to end-stage liver disease in patients with HIV infection. Clin Infect Dis 2001;32:492-7
   PubMed Web of Science ®Google Scholar
• Kramer J, Giordano T, Souchek J, El-Serag HB. Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. J Hepatol 2005;42:309-14
   PubMed Web of Science ®Google Scholar
• Clark S, Creighton S, Portmann B, Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases. J Hepatol 2002;36:295-301
   PubMed Web of Science ®Google Scholar
• Selik R, Byers R, Dworkin M. Trends in diseases reported on US death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr 2002;29:378-87
   PubMed Web of Science ®Google Scholar
• Abrescia N, D'Abbraccio M, Figoni M, Hepatotoxicity of antiretroviral drugs. Curr Pharma Des 2005;11:3697-10
   PubMed Web of Science ®Google Scholar
• Keeffe, EB, Friedman LM. Handbook of liver diseases. Churchill Livingstone: Edinburgh; 2004. p. 104-23
   Google Scholar
• Smilkstein MJ, Bronskin AC, Linden C, Acetaminophen overdose: a 48-h intravenous N-acetylcysteine treatment protocol. Ann Emerg Med 1991;20:1058-63
   PubMed Web of Science ®Google Scholar
• Bonkowsky HL, Mudge GH, McMurtry RJ. Chronic hepatic inflammation and fibrosis due to low doses of paracetamol. Lancet 1978:13:1016-8
   Google Scholar
• Bridger S, Henderson K, Glucksman E, Deaths from low dose paracetamol poisoning. BMJ 1998;316:1724-5
   PubMed Web of Science ®Google Scholar
• James LP, Mayeux PR, Hinson JA. Acetaminophen-induced hepatotoxicity. Drug Metab. Dispo 2003;31:1499-06
   PubMed Web of Science ®Google Scholar
• Whittaker SJ, Amar JN, Wanless IR, Heathcote J. Sulindac hepatotoxicity. Gut 1982;23:875-877
   PubMed Web of Science ®Google Scholar
• Aithal GP, Day CP. Nonsteroidal anti-inflammatory druginduced hepatotoxicity. Clin. Liver Dis 2007;11:563-75
   Google Scholar
• Garcia Rodriguez LA, Walker AM, Perez Gutthann S. Nonsteroidal anti-inflammatory drugs and gastrointestinal hospitalizations in Saskatchewan: a cohort study. Epidemiology 1992;3:337-42
   PubMed Web of Science ®Google Scholar
• Zou W, Devi SS, Sparkenbaugh E, Hepatotoxic Interaction of Sulindac with Lipopolysaccharide: Role of the Hemostatic System. Toxicol sci 2009;108:184-93
   PubMed Web of Science ®Google Scholar
• Wassel R, Brinker A. An evaluation of hepatic events associated with telithromycin (within Briefing Document, Division of Drug Risk Evaluation Office of Surveillance and Epidemiology, pages 23-50). June 11:
   Google Scholar
• Brinker AD, Wassel RT, Lyndly J, Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology 2009;49:250-7
   PubMed Web of Science ®Google Scholar
• Onur O, Guneysel O, Denizbasi A, Celikel C. Acute hepatitis attack after exposure to telithromycin. Clin Ther 2007;29:1725-29
   PubMed Web of Science ®Google Scholar
• Dore DD, DiBello JR, Lapane KL. Telithromycin use and spontaneous reports of hepatotoxicity. Drug Saf 2007;30:697-03
   PubMed Web of Science ®Google Scholar
• Heaton PC, Fenwick SR, Brewer DE. Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study. J Clin Pharm Ther 2007;32:483-7
   PubMed Web of Science ®Google Scholar
• Burnham T, editor. Drug facts and comparisons. Wolter Kluwer Co.: St. Louis, MO; 2001. p. 1332
   Google Scholar
• Westphal JF, Vetter D, Brogard JM. Hepatic side-effects of antibiotics. J Antimicrob Chemother 1994;33:387-01
   PubMed Web of Science ®Google Scholar
• George DK, Crawford DH. Antibacterial-induced hepatotoxicity. Incidence, prevention and management. Drug Saf 1996;15:79-85
   PubMed Web of Science ®Google Scholar
• Asha K, Sankar TV, Nair PG. Effect of tetracycline on pancras and liver functions of adult male albino rats. J Pharm Pharmacol 2007;59:1241-48
   PubMed Web of Science ®Google Scholar
• Navaro VJ, Senior JR. Drug-related hepatoxicity. New Eng J Med 2006; 731-739
   PubMed Web of Science ®Google Scholar
• Melnik G, Schwesinger W, Teng H, Hepatobiliary elimination of trovafloxacin and metabolites following single oral doses in healthy volunteers. Eur J Clin Microbiol Infect Dis 1998;17:424-26
   PubMed Web of Science ®Google Scholar
• Ball P, Mandell L, Niki Y, Tillotson G. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf 1999;21:407-21
   PubMed Web of Science ®Google Scholar
• Colletti LM, Remick DG, Burtch GD, Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat. J Clin Invest 1990;85:1936-43
   PubMed Web of Science ®Google Scholar
• Zhang D. Tumour necrotic factor (TNF) in the pathogenesis of liver necrosis in viral hepatitis and strategy for its prevention and treatment. Zhonghua Yi Xue Za Zhi 1990;70:438-41
   PubMedGoogle Scholar
• Chen HJ, Bloch KJ, Maclean JA. Acute eosinophilic hepatitis from trovafloxacin. N Engl J Med 2000;342:359-60
   PubMed Web of Science ®Google Scholar
• Lazarczyk DA, Goldstein NS, Gordon SC. Trovafloxacin hepatotoxicity. Dig Dis Sci 2001;46:925-26
   PubMed Web of Science ®Google Scholar
• Lucena MI, Andrade RJ, Gomez-outes A, Acute liver failure after treatment with nefazodone. Dig Dis Sci 1999;44:2577-79
   PubMed Web of Science ®Google Scholar
• Chu AG, Gunsolly BL, Summers RW, Trazodone and liver toxicity. Ann Internm Med 1983;99:128-9
   PubMed Web of Science ®Google Scholar
• Longstreth GF, Hershman J. Trazodone-induced hepatotoxicity and leukonychia. J Am Acad Dermatol 1985;13:149-50
   PubMed Web of Science ®Google Scholar
• Beck PL, Bridges RJ, Demetrick DJ, Chronic active hepatitis associated with trazodone therapy. Ann Intern Med 1993;118:791-92
   PubMed Web of Science ®Google Scholar
• Hull M, Jones R, Bendall M. Fatal hepatic necrosis associated with trazodone and neuroleptic drugs. Br Med J 1994; 309:378
   PubMed Web of Science ®Google Scholar
• Fernandes NF, Martin RR, Schenker S. Trazodone-induced hepatotoxicity: a case report with comments on drug-induced hepatotoxicity. Am J Gastroenterol 2000;95:532-35
   PubMed Web of Science ®Google Scholar
• Rettman KS, McClintock C. Hepatotoxicity after short-term trazodone therapy. Ann Pharmacother 2001;35:1559-61
   PubMed Web of Science ®Google Scholar
• Abusin S, Johnson S. Sulfamethoxazole/Trimethoprim induced liver failure: a case report. Cases J 2008;1:44
   PubMedGoogle Scholar
• Ransohoff DF, Jacobs G. Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim. Gastroenterology 1981;80:816-19
   PubMed Web of Science ®Google Scholar
• Yao F, Behling CA, Saab S, Trimethoprimsulfamethoxazole induced vanishing bile duct syndrome. AmJ Gastroenterology 1997;92:167-69
   PubMed Web of Science ®Google Scholar
• Altraif I, Lilly L, Wanless IR, Heathcote J. Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprimsulfamethoxazole. Am J Gastroenterol 1994;89:1230-34
   PubMed Web of Science ®Google Scholar
• Hall M, Monka C, Krupp P, O'sullivan D. Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol 1997;133(10):1213-9
   PubMed Web of Science ®Google Scholar
• Chang CH, Young-Xu Y, Kurth T, The safety of oral antifungal treatments for superfi cial dermatophytosis and onychomycosis: a meta-analysis. Am J Med 2007;120:791-98
   PubMed Web of Science ®Google Scholar
• Agarwal K, Manas DM, Hudson M. Terbinafi ne and fulminant hepatic failure. N Engl J Med 1999;340:1292-93
   PubMed Web of Science ®Google Scholar
• Fernandes NF, Geller SA, Fong TL. Terbinafine hepatotoxicity: case report and review of the literature. Am J Gastroenterol 1998;93:459-60
   PubMed Web of Science ®Google Scholar
• Brown PC. NDA 22-047; Lamisil® (terbinafine hydrochloride) Oral Granules. In: Administration FaD, editor; 2007
   Google Scholar
• Lowe G, Green C, Jennings P. Hepatitis associated with terbinafi ne treatment. BMJ. 1993;306:248
   PubMed Web of Science ®Google Scholar
• Paredes AH, Lewis JH. Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infection. Ann Pharmacother 2007;41:880-4
   PubMed Web of Science ®Google Scholar
• Spahr L, Rubbia-Brandt L, Burkhard PR, Tolcapone-related fulminant hepatitis: electron microscopy shows mitochondrial alterations. Dig Dis Sci 2000;45:1881-84
   PubMed Web of Science ®Google Scholar
• Assal F, Spahr L, Hadengue A, Tolcapone and fulminant hepatitis. Lancet 1998;352:9132
   Google Scholar
• Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis 2009;29:412-22
   PubMed Web of Science ®Google Scholar
• Feng B, Xu JJ, Bi YA, Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714. Toxicol Sci 2009;108:492-500
   PubMed Web of Science ®Google Scholar
• Sipe WE, Su M, Posselt A, Propylthiouracil-associated liver failure presenting as probable autoimmune hepatitis in a child with Graves' disease. Pediatr Transplant 2006;10:525-28
   PubMed Web of Science ®Google Scholar
• Tran A, Housset C, Boboc B, Etoposide (VP-213) induced hepatitis. Report of three cases following standard-dose treatments. J Hepatol 1991;12:36-9
   PubMed Web of Science ®Google Scholar
• Chaudhry M, Maqsood A, Diab-Agha S, Rosenberg J. Nicardipine-induced acute hepatitis in an intensive care unit patient. Am J Ther 2009;16:71-3
   PubMed Web of Science ®Google Scholar
• Pritchard J, Raine J, Wallendszus K. Hepatotoxicity of actinomycin-D. Lancet 1989;1:168
   PubMed Web of Science ®Google Scholar
• Ludwig R, Weirich A, Abel U, Hepatotoxicity in patients treated according to the nephroblastoma trial and study SIOP-9/GPOH. Med Pediatr Oncol 1999;33:462-69
   PubMedGoogle Scholar
• Carrascosa MF, Lucena MI, Andrade RJ, Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute Mycoplasma pneumoniae infection. Clin Ther 2009;31:1014-19
   PubMed Web of Science ®Google Scholar
• van Iersel LB, Verlaan MR, Vahrmeijer AL, Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: a clinical and pharmacologic evaluation. Eur J Surg Oncol 2007;33:874-81
   PubMed Web of Science ®Google Scholar
• Dara L, Hewett J, Lim JK. Hydroxycut hepatotoxicity: a case series and review of liver toxicity from herbal weight loss supplements. World J Gastroenterol 2008;14:6999-04
   PubMed Web of Science ®Google Scholar
• Sanchez W, Maple JT, Burgart LJ, Kamath PS. Severe hepatotoxicity associated with use of a dietary supplement containing usnic acid. Mayo Clin Proc 2006;81:541-44
   PubMed Web of Science ®Google Scholar
• Neff GW, Reddy KR, Durazo FA, Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. J Hepatol 2004;41:1062-64
   PubMed Web of Science ®Google Scholar
• Niemczyk M, Wyzgał J, Perkowska A, Sirolimus-associated hepatotoxicity in the kidney graft recipient. Transpl Int 2005;18:1302-03
   PubMed Web of Science ®Google Scholar
• Neff GW, Ruiz P, Madariaga JR, Sirolimus-associated hepatotoxicity in liver transplantation. Ann Pharmacother 2004;38:1593-96
   PubMed Web of Science ®Google Scholar
• Singhal S, Gray T, Grace G, Sevoflurane hepatotoxicity: a case report of sevoflurane hepatic necrosis and review of the literature. Am J Ther 2009. Published online on May 19
   Google Scholar
• Lehmann A, Neher M, Kiessling AH, Case report: fatal hepatic failure after aortic valve replacement and sevoflurane exposure. Can J Anaesth 2007;54:917-21
   PubMed Web of Science ®Google Scholar
• Turillazzi E, D'Errico S, Neri M, A fatal case of fulminant hepatic necrosis following sevoflurane anesthesia. Toxicol Pathol 2007;35:840-45
   PubMed Web of Science ®Google Scholar
• Jang Y, Kim I. Severe hepatotoxicity after sevoflurane anesthesia in a child with mild renal dysfunction. Paediatr Anaesth 2005;15:1140-44
   PubMed Web of Science ®Google Scholar
• García-Buey L, García-Monzón C, Rodriguez S, Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995;108:1770-77
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Miller FN, Sims DE, Mechanisms of interleukin-2-induced hepatic toxicity. Cancer Res 1996;56:507-10
   PubMed Web of Science ®Google Scholar
• Cavalli F, Tschopp L, Sonntag RW, Zimmermann A. Cisplatin-induced hepatic toxicity. Cancer Treat Rep 1978;62:2125-26
   PubMedGoogle Scholar
• Cersosimo RJ. Hepatotoxicity associated with cisplatin chemotherapy. Ann Pharm 1993;27:438-41
   PubMed Web of Science ®Google Scholar
• Cohen DL, Del Toro Y. A case of valerian-associated hepatotoxicity. J Clin Gastroenterol 2008;42:961-62
   PubMed Web of Science ®Google Scholar
• Castiella A, Arenas JI. Fluoxetine hepatotoxicity. Am J Gastroenterol 1994;89:458-59
   PubMed Web of Science ®Google Scholar
• Cai Q, Benson MA, Talbot TJ, Acute hepatitis due to fluoxetine therapy. Mayo Clin Proc 1999;74:692-94
   PubMed Web of Science ®Google Scholar
• Robles M, Andrade RJ. Hepatotoxicity by antibiotics: update in 2008. Rev Esp Quimioter 2008;21:224-33
   PubMed Web of Science ®Google Scholar
• Actis GC, Debernardi-Venon W, Lagget M, Hepatotoxicity of intravenous cyclosporin A in patients with acute ulcerative colitis on total parenteral nutrition. Liver 1995;15:320-33
   PubMedGoogle Scholar
• Chicharro M, Guarner L, Vilaseca J, Does cyclosporin A worsen liver function in patients with inflammatory bowel disease and total parenteral nutrition? Rev Esp Enferm Dig 2000;92:68-77
   PubMedGoogle Scholar
• Taniai N, Akimaru K, Ishikawa Y, Hepatotoxicity caused by both tacrolimus and cyclosporine after living donor liver transplantation. J Nippon Med Sch 2008;75:187-91
   PubMedGoogle Scholar
• Koulaouzidis A, Bhat S, Moschos J, Nitrofurantoin-induced lungand hepatotoxicity. Ann Hepatol 2007;6:119-21
   PubMed Web of Science ®Google Scholar
• Chang KC, Leung CC, Yew WW, Hepatotoxicity of Pyrazinamide. Am J Respir Crit Care Med 2008;177:1391-96
   PubMed Web of Science ®Google Scholar
• Reddy KR, Schiff ER. Hepatotoxicity of antimicrobial, antifungal, and antiparasitic agents. Gastroenterol Clin North Am 1995;24:923-36
   PubMed Web of Science ®Google Scholar
• Thiim M, Friedman LS. Hepatotoxicity of antibiotics and antifungals. Clin Liver Dis 2003;7:381-99
   PubMedGoogle Scholar
• Licata A, Calvaruso V, Cappello M, Clinical course and outcomes of drug-induced liver injury: Nimesulide as the first implicated medication. Dig Liver Dis 2009. Published online July 2009
   PubMedGoogle Scholar
• Nelson SD and Pearson PG. Covalent and noncovalent interactions in acute lethal cell injury caused by chemicals. Annu Rev Pharmacol Toxicol 1990;30:169-95
   PubMed Web of Science ®Google Scholar
• Hinson JA, Roberts DW. Role of covalent and noncovalent interactions in cell toxicity: effects on proteins. Annu Rev Pharmacol Toxicol 1992;32:471-10
   PubMed Web of Science ®Google Scholar
• Boelsterli UA. Specific targets of covalent drug-protein interactions in hepatocytes and their toxicological significance in drug-induced liver injury. Drug Metab Rev 1993;25:359-51
   Google Scholar
• Pohl LR, Sato H, Christ DD, Kenna JG. The immunologic and metabolic basis of drug hypersensitivities. Annu Rev Pharmacol Toxicol 1988;28:367-87
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, Madden S Park BK. Idiosyncratic drug reactions: Metabolic bioactivation as a pathogenic mechanism. Clin Pharmacokinet 1996;31:215-30
   PubMed Web of Science ®Google Scholar
• Xu C, Li CY, Kong AN. Induction of Phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 2005;28:249-68
   PubMed Web of Science ®Google Scholar
• Pessayre D. Role of reactive metabolites in drug-induced hepatitis. J Hepatol 1995;23(S):16-24
   PubMedGoogle Scholar
• Fau D, Lekehal M, Farrell G, Diterpenoids from german-der, a herbal medicine, induce apoptosis in isolated rat hepatocytes. Gastroenterology 1997;113:1334-46
   PubMed Web of Science ®Google Scholar
• Robin MA, Maratrat M, Le Roy M, Antigenic targets in tienilic acid hepatitis. Both cytochrome P450 2C11 and 2C11-tienilic acid adducts are transported to the plasma membrane of rat hepatocytes and recognized by human sera. J Clin Invest 1996;98:1471-18
   PubMed Web of Science ®Google Scholar
• Fromenty B, Pessayre D. Inhibition of mitochondrial b-oxida- tion as a mechanism of hepatotoxicity. Pharmacol Ther 1995;67:101-54
   PubMed Web of Science ®Google Scholar
• Fromenty B, Berson A, Pessayre D. Microvesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxidation. J Hepatol 1997;26(Suppl 1):13-22
   PubMedGoogle Scholar
• Acikgöz A, Karim N, Giri S, Two compartment model of diazepam biotransformation in an organotypical culture of primary human hepatocytes. Toxicol Appl Pharmacol 2009;234:179-91
   PubMed Web of Science ®Google Scholar
• Sidhu JS, Farin FM, Omiecinski CJ. Influence of extracellular matrix overlay on phenobarbital-mediated induction of CYP2B1, 2B2, and 3A1 genes in primary adult rat hepatocyte culture. Arch Biochem Biophys 1993;301:103-13
   PubMed Web of Science ®Google Scholar
• Sidhu JS, Liu F, Omiecinski CJ. Phenobarbital responsiveness as a uniquely sensitive indicator of hepatocyte differentiation status: requirement of dexamethasone and extracellular matrix in establishing the functional integrity of cultured primary rat hepatocytes. Exp Cell Res 2004;292:252-64
   Web of Science ®Google Scholar
• Bader A, Zech K, Crome O, Use of organotypical cultures of primary hepatocytes to analyse drug biotransformation in man and animals. Xenobiotica 1994;24:623-33
   PubMed Web of Science ®Google Scholar
• Staack RF, Hopfgartner G. New analytical strategies in studying drug metabolism. Anal Bioanal Chem 2007;388:1365-80
   PubMed Web of Science ®Google Scholar
• Kern A, Bader A, Pichlmayer R, Sewing KF. Drug metabolism in hepatocyte sandwich cultures of rats and humans. Biochem Pharmacol 1997;54:761-72
   PubMed Web of Science ®Google Scholar
• Fouts JR. The stimulation and inhibition of hepatic microsomal drug-metabolizingenzymes with special reference to effects of environmental contaminants. Toxicol Appl Pharmacol 1970;17:804-09
   PubMed Web of Science ®Google Scholar
• Albert PL. Accurate prediction of human drug toxicity: a major challenge in drug development. Chem Biol Interact 2004;150:3-7
   PubMed Web of Science ®Google Scholar
• Andrade RJ, Robles M, Fernández-Castañer A, Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J Gastroenterol 2007;3:329-40
   Google Scholar
• Shah RR. Drug-induced hepatotoxicity: pharmacokinetic perspectives and strategies for risk reduction. Adverse Drug React Toxicol Rev 1999;18:181-33
   PubMedGoogle Scholar
• Friedman SE, Grendell JH, McQuaid KR. Current diagnosis & treatment in gastroenterology. Lang Medical Books/McGraw-Hill: New York; 2003. p. 664-679
   Google Scholar
• Ragan I. The innovative medicines initiative: a proposal with implications for the 3Rs, 7, 1-6. Available from: http://www.nc3rs.org.uk/downloaddoc.asp?id=378&page=246&skin=0. [Last accessed 30 March 2010]
   Google Scholar
• Jeffrey P, Warne P, Williams R. Addressing the innovation gap, Drug News Perspect 2007;20:265-269
   PubMedGoogle Scholar
• Ma S, Zhu M. Recent advances in applications of liquid chromatography–tandem mass spectrometry to the analysis of reactive drug metabolites. Chem Biol Interact 2009;179:25-37
   PubMed Web of Science ®Google Scholar
• Gerber BO, Pichler WJ. Noncovalent interactions of drugs with immune receptors may mediate drug-induced hypersensitivity reactions. AAPS J 2006;8:160-5
   Google Scholar
• Pang KS, Xin X, Stpierre MV. Determinants of metabolite disposition. Ann Rev Pharmacol Toxicol 1992;32:623-69
   PubMed Web of Science ®Google Scholar
• Evans AM. Membrane transport as a determinant of the hepatic elimination of drugs and metabolites. Clin Exp Pharmacol Physiol 1996;23:970-74
   PubMed Web of Science ®Google Scholar
• Smith DA, Obach RS, Seeing through the MIST. Abundance versus percentage. Commentary onmetabolites in safety testing. Drug Metab Dispos 2005;33:1409-17
   PubMed Web of Science ®Google Scholar
• Smith DA, Obach RS. Metabolites and safety: what are the concerns, and how should we address them? Chem Res Toxicol 2006;12:1570-79
   Google Scholar
• Smith DA, Obach RS, Williams DP, Park BK. Clearing the MIST (metabolites in safety testing) of time: the impact of duration of administration on drug metabolite toxicity. Chem Biol Interact 2009;179:60-7
   PubMed Web of Science ®Google Scholar